A. Ghofrani (Giessen, Germany), S. Gaine (Dublin, Ireland)
Effect of interferon α preparations on IP10 and ET-1 release from human pulmonary artery smooth muscle cells
R. Badiger, T. Manigold, H. Gashaw, H. J. Hinton, T. Singer, P. M. George, T. T. Hansel, J. A. Mitchell (London, United Kingdom; Basel, Switzerland)
|   |
Could platelet-activating factor acetylhydrolase (PAF-AH) predict adverse event in pulmonary hypertension?
R. Quarck, H. Durand, E. Ninio, M. Delcroix (Leuven, Belgium; Paris, France)
| |
Hypoxia-mediated alterations in adenosine receptor expression in rat lung
J. Salys, A. Kratzer, M. Zamora, L. Taraseviciene-Stewart (Aurora, United States Of America)
| |
Potential contribution of precursor cells to vascular remodeling in the AdTGF-β1 model of lung fibrosis and pulmonary hypertension
L. Farkas, D. Farkas, D. Kraskauskas, J. Gauldie, M. Kolb, N. Voelkel (Richmond, United States Of America; Hamilton, Canada)
| |
Caspase inhibition reduces severe pulmonary hypertension in the AdTGF-1β/SU5416 model of angioproliferative pulmonary hypertension and lung fibrosis
L. Farkas, D. Farkas, D. Kraskauskas, J. Gauldie, M. Kolb, N. Voelkel (Richmond, United States Of America; Hamilton, Canada)
| |
Effects of type I, II and III interferons on endothelin-1 release by human pulmonary artery smooth muscle cells
P. M. George, R. Badiger, H. Gashaw, N. Galloway-Phillipps, T. T. Hansel, J. A. Mitchell (London, United Kingdom)
| |
Roles of sex hormones on bone morphogenetic protein signaling in pulmonary artery differed between testosterone and estrogen
H. Ichimori, S. Kogaki, K. Takahashi, K. Ozono (Suita, Japan)
| |
Pulmonary hypertension in the newborn GTP-cyclohydrolase 1 deficient mouse is unrelated to endothelium-dependent vasorelaxation potential
J. Belik, B. McIntyre, J. Pan, J. Vasquez-Vivar (Toronto, Canada; Milwaukee, United States Of America)
| |
Autoimmunity and pulmonary arterial hypertension: The role of leptin
A. Huertas, D. Montani, N. Gambaryan, F. Perros, B. Girerd, S. Cohen-Kaminsky, M. Humbert (Le Plessis-Robinson, Clamart, France)
| |
Risk factors for elevated liver function tests (eLFTs) in patients with pulmonary arterial hypertension (PAH) treated with sitaxentan and followed in a European safety registry
L. J. Hwang, J. Teeter, M. Louie, H. Toft Sørensen, C. de Luise (New York, United States Of America; Aarhus, Denmark)
| |
Increased p130Cas activity induces smooth muscle cell proliferation and migration in idiopathic pulmonary arterial hypertension
L. Tu, F. De Man, F. Lecerf, C. François, P. Dartevelle, G. Simonneau, E. Fadel, M. Humbert, S. Eddahibi, C. Guignabert (Le Plessis-Robinson, France; Amsterdam, Netherlands)
| |
Ghrelin effects on local renin angiotensin from pulmonary vessels
I. L. Dumitriu, E. Cojocaru, L. G. Vata, M. Costuleanu, B. Gurzu, S. M. Slatineanu (Iasi, Romania)
| |
Nestin expressing progenitor cells in pulmonary vasculature
F. Saboor, C. Berndt, N. Weissmann, R. Schermuly, D. Müller, R. Middendorff (Giessen, Germany)
| |
Endothelial cell mechanics are altered in pulmonary arterial hypertension (PAH)
C. Hardin, R. Krishnan, D. Tambe, S. Sheik, G. Manomohan, J. Fredberg, A. Waxman (Boston, United States Of America)
| |
Involvement of cytoskeletal protein paxillin in the pathogenesis of pulmonary hypertension
C. Veith, W. Seeger, N. Weissmann, G. Kwapiszewska (Giessen, Germany)
| |
Determination of cell-derived microparticles in patients with pulmonary hypertension and connective-tissue diseases using flow cytometry
X. Kqiku, G. Kovacs, E. Rohde, D. Strunk, H. Olschewski (Graz, Salzburg, Austria)
| |
The role of the accessory type III transforming growth factor-β receptors in the regulation of pulmonary vascular development
G. Niess, M. Michiels-Corsten, W. Seeger, R. Morty (Bad Nauheim, Germany)
| |
Elevated levels of adenosine in the lungs lead to chronic lung injury and pulmonary hypertension
H. Karmouty-Quintana, H. Zhong, D. Zeng, L. Belardinelli, M. Blackburn (Houston, Palo Alto, United States Of America)
| |